A pilot study to optimise the use of FDG PET-CT and deformable image co-registration for lymphoma radiotherapy planning

eeds Teaching Hospitals NHS Trust0 个研究点目标入组 19 人开始时间: 2016年6月28日最近更新: 2023年7月25日

适应症

试验速览

2018 Results article in https://pubmed.ncbi.nlm.nih.gov/30246160/ (added 10/07/2023)

•1. Age =18 years
•2. WHO Performance status 0-2 (Appendix A)
•3. Histologically proven Hodgkin lymphoma or high grade non-Hodgkin lymphoma
•4. Ann Arbor Stage I/II disease based upon clinical examination and any radiology investigations performed
•5. Clinical decision to proceed with sequential chemotherapy and radiotherapy if stage I/II disease is confirmed on subsequent PET-CT staging
•6. Residual disease in situ after biopsy (either palpable or on any imaging acquired pre-PET-CT)
•7. Able to provide fully informed written consent
•8. Able to lie flat for 1 hour
•9. Not be pregnant or breast feeding. Female patients of childbearing potential must agree to use effective contraception, be surgically sterile, or be post-menopausal

•1. Hypersensitivity to 18Fluorine-FDG
•2. Hypersensitivity to iodinated contrast media
•3. Poorly controlled diabetes
•4. Acute renal failure or moderate renal impairment (estimated glomerular filtration rate < 30 mL/min)
•5. Uncontrolled pain
•6. Urinary incontinence
•7. Female patients must not be pregnant and if of child bearing age using adequate contraception
•8. Breast feeding
•9. Serious psychiatric comorbidity

发起方

eeds Teaching Hospitals NHS Trust